Blog
RSS FeedPosted by Michael Wonder on 29 Aug 2024
Pembrolizumab in combination with platinum- and fluoropyrimidine-based chemotherapy for the treatment of patients with advanced HER2 negative gastric or gastro-oesophageal junction adenocarcinoma
29 August 2024 - NICE has published final evidence-based recommendations on the use of pembrolizumab (Keytruda) in combination with platinum- ...
Posted by Michael Wonder on 25 Aug 2024
Risankizumab for the treatment of patients with moderately to severely active ulcerative colitis
23 August 2024 - NICE has published final evidence-based recommendations on the use of risankizumab (Skyrizi) for the treatment of ...
Posted by Michael Wonder on 22 Aug 2024
Benefits of new Alzheimer’s treatment lecanemab are too small to justify the cost to the NHS
22 August 2024 - Our draft recommendation follows analysis of clinical trial evidence and reviewing the benefits of slowing disease progression, ...
Posted by Michael Wonder on 14 Aug 2024
Linzagolix choline for the treatment of patients with moderate to severe symptoms of uterine fibroids (final guidance)
14 August 2024 - NICE has published final evidence-based recommendations on the use of linzagolix choline (Yselty) for the treatment ...
Posted by Michael Wonder on 14 Aug 2024
Relugolix for the treatment of patients with hormone sensitive prostate cancer
14 August 2024 - NICE has published final evidence-based recommendations on the use of relugolix (Orgovyx) for the treatment of ...
Posted by Michael Wonder on 09 Aug 2024
Enzalutamide for the treatment of patients with non-metastatic prostate cancer after radical prostatectomy or radiotherapy
8 August 2024 - NICE is unable to make a recommendation about the use in the NHS of enzalutamide for the ...
Posted by Michael Wonder on 08 Aug 2024
World’s first gene editing therapy for blood disorder to be available to hundreds of patients in England
8 August 2024 - Patients in England with severe beta-thalassaemia will be amongst the first in Europe to benefit from one-time ...
Posted by Michael Wonder on 07 Aug 2024
14,000 women at risk of fractures after the menopause to benefit from bone disease drug
8 August 2024 - Over 14,000 people to benefit after NICE published final guidance recommending abaloparatide as an option for treating ...
Posted by Michael Wonder on 07 Aug 2024
Burosumab for the treatment of adults with X-linked hypophosphataemia
7 August 2024 - NICE has issued evidence-based recommendations on the use burosumab (Crysvita) for the treatment of adults X‑linked ...
Posted by Michael Wonder on 07 Aug 2024
Abaloparatide for the treatment of women with osteoporosis after menopause
6 August 2024 - NICE has issued dvidence-based recommendations on the use of abaloparatide (Eladynos) for treatment of osteoporosis after ...
Posted by Michael Wonder on 30 Jul 2024
NICE disappointed companies unwilling to offer fair price to make Enhertu available for advanced breast cancer
29 July 2024 - Daiichi Sankyo and partner company AstraZeneca have been unwilling to offer a price that would enable NICE ...
Posted by Michael Wonder on 25 Jul 2024
New clot busting drug recommended by NICE set to save NHS millions of pounds
24 July 2024 - Giving a new clot busting drug to people who have had a stroke could help save the ...
Posted by Michael Wonder on 19 Jul 2024
More than 40,000 people could benefit after NICE recommends new ‘take at home’ pill for advanced prostate cancer
19 July 2024 - A new pill to treat advanced hormone sensitive prostate cancer that could benefit just over 40,000 ...
Posted by Michael Wonder on 10 Jul 2024
NICE recommends Ebglyss (lebrikizumab) for use in moderate to severe atopic dermatitis in the NHS England in eligible adolescents and adults
10 July 2024 - Following approval of the European Commission (October 2023) and the MHRA (December 2023), lebrikizumab will be available ...
Posted by Michael Wonder on 10 Jul 2024
Lisocabtagene maraleucel for the treatment of adults with relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma
10 July 2024 - NICE is unable to make a recommendation about the use in the NHS of lisocabtagene maraleucel (Breyanzi) ...